Boston Scientific Shares Rising Higher

The company develops, manufactures, and markets medical devices. Its primary segments include MedSurg (endoscopy, urology, and neuromodulation) and Cardiovascular (cardiology and peripheral interventions). According to analysts, BSX’s innovative product pipeline is expected to yield many differentiated product launches in the future.

Financially, the company’s performance is surpassing long-term internal expectations. The company’s upcoming per-share earnings are projected to be $0.58 for the quarter, which would be a 16% increase compared to the previous year. The consensus estimate calls for revenue of $4.03 billion, up 14.3% from the prior-year quarter. For the whole year, analysts predict earnings of $2.40 per share and revenue of $16.3 billion, reflecting growth of 17.1% and +14.2%, respectively, compared to 2023.

It’s no wonder BSX shares are up 41% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Boston Scientific Under Heavy Demand

Institutional volumes reveal plenty. Recently, BSX has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in BSX shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Boston Scientific.

Boston Scientific Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, BSX has had strong sales and earnings growth:

• 3-year sales growth rate (+13%)
• 3-year EPS growth rate (+52.8%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +13.3%.

Now it makes sense why the stock has been powering to new heights. BSX has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Boston Scientific has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when BSX was a top pick…sending shares higher:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Boston Scientific Price Prediction

The BSX rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in BSX at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.